1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

0.59
EUR
-0.03
(-4.30%)
11.11BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.46
0.59
0.73
0.81
0.89
1.13
1.29
1.26
1.43
1.4
1.41
1.58
1.77
- -
Basic EPS, GAAP
0.05
0.07
0.09
0.1
0.13
0.49
0.15
0.15
0.78
0.14
0.13
0.19
0.13
- -
Free Cash Flow per Basic Share
0.05
0.08
0.05
0.13
0.14
0.18
0.19
0.18
0.19
0.24
0.24
0.29
0.42
- -
Dividend per Share
0.01
0.02
0.01
0.02
0.03
0.04
0.04
0.06
0.05
0.07
0.03
0.1
0.08
- -
Book Value per Share
0.26
0.32
0.39
0.47
0.55
0.69
0.79
0.89
1.61
1.61
1.66
1.78
1.71
1.61
Tangible Book Value per Share
0.25
0.3
0.37
0.46
0.53
0.52
0.65
0.83
1.52
1.51
1.5
1.61
1.32
1.52
Basic Weighted Avg Shares
16,677
16,677
16,677
16,677
16,677
18,549
18,811
18,800
18,769
18,622
18,529
18,294
18,002
18,796
Sales/Revenue/Turnover
7,737
9,898
12,184
13,543
14,819
20,889
24,234
23,647
26,861
26,026
26,199
28,866
31,834
- -
Operating Margin (%)
17.8
18.43
19.55
20.38
22.01
20.68
21.45
18.2
16.21
21.05
23.23
21.94
21.67
- -
Depreciation Expense
175
207
296
317
343
1,176
1,446
1,655
993
1,047
1,074
1,321
1,212
- -
Net Income, GAAP
810
1,210
1,489
1,637
2,171
9,046
2,762
2,771
14,608
2,544
2,332
3,500
2,343
- -
Effective Tax Rate (%)
16.59
15.71
15.47
14.83
12.92
6.09
15.86
13.41
10.54
13.36
14.74
9.34
23.46
- -
Profit Margin (%)
10.47
12.22
12.22
12.09
14.65
43.31
11.4
11.72
54.38
9.77
8.9
12.12
7.36
- -
Working Capital
2,537
3,454
3,697
7,076
8,092
8,798
16,790
11,851
8,158
5,784
1,199
5,129
9,266
8,158
LT Debt
- -
1,030
257
1,679
2,210
555
7,926
12,628
5,532
4,258
1,373
2,080
7,651
5,532
Total Equity
5,646
7,051
8,742
10,678
12,611
17,779
20,561
22,420
37,729
37,944
38,170
42,774
42,086
37,729
Return on Invested Capital (%)
34.46
23.33
23.75
32.85
18.89
54.57
17.15
11.24
8.91
9.41
9.96
9.05
9.33
- -
Return on Capital (%)
4.42
7.94
6.42
5.11
5.16
40.74
3.68
4.5
29.78
0.9
-0.02
1.75
-0.75
- -
Return on Common Equity (%)
20.31
25.28
25.29
22.75
25.37
81.39
19.75
17.49
62.11
8.47
7.74
11.21
7.48
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'21
Jun'21
Dec'21
ST Debt
1,225
1,846
6,585
LT Borrowings
12,317
11,516
5,213
LT Finance Leases
264
291
320
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18,862
18,862
18,840
Market Capitalization
- -
- -
80,216

Working Capital

CNY

•

in mil. unless spec.
Mar'21
Jun'21
Dec'21
Total Current Assets
21,791
23,813
23,503
Cash, Cash Equivalents & STI
10,337
10,443
15,794
Accounts Receivable, Net
3,251
5,059
3,275
Inventories
1,813
1,732
1,938
Total Current Liabilities
10,358
11,485
15,345
Payables & Accruals
- -
- -
- -
ST Debt
1,225
1,846
6,585
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.58%
15.98%
-1.61%
Free Cash Flow
31.52%
18.44%
45.35%
Net Income, GAAP
64.34%
70.66%
-33.04%
Sales/Revenue/Turnover
10.68%
6.32%
10.28%
Total Cash Common Dividend
32.64%
27.45%
-18.62%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
26,199
2024
- -
- -
28,866
2025
- -
- -
31,834

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.13
2024
- -
- -
0.19
2025
- -
- -
0.13

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.03
2024
- -
- -
0.1
2025
- -
- -
0.08

Company Description

Company Profile APIChatGPT
CEO
S Y Tse
Full Time Employees
21,435
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Unit 09, Office Tower Hong Kong Hong Kong
IPO Date
Dec 8, 2003
Website
sinobiopharm.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sino Biopharmaceutical Limited (1177.HK) is an investment holding company engaged in the research, development, manufacture, and sale of Chinese medicines and Western medicines. The company operates through segments including Chinese medicines, Western medicines, investment management, medical aesthetics, and others; its core products and services encompass a wide range of pharmaceuticals such as anti-tumor drugs, cardio-cerebral vascular drugs, anti-infective medicines, and traditional Chinese medicine formulations including QiKangSu oral liquid and Kanglaite injection, alongside medical aesthetic products and healthcare services. Founded in 1999 and headquartered in Hong Kong, the company primarily serves the healthcare markets in the People's Republic of China with international distribution in select regions. In recent developments, Sino Biopharmaceutical has pursued strategic expansions including partnerships for innovative drug development and commercialization, alongside ongoing investments in R&D for new oncology and chronic disease therapies within the last two years.

Company News

Company News APIChatGPT

  • reuters.com

    Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

  • wsj.com

    AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

  • reuters.com

    Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

  • reuters.com

    Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

  • forbes.com

    Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea

  • seekingalpha.com

    Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day